Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

TPEX/6539 stock hub

TPEX/6539 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TPEX/6539is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.2B

Taipei Exchange

Market data

Live price

Current market quote for this ticker.

Current price

TPEX/6539

In the news

Latest news · TPEX/6539

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12P50 15.5P75 22.5

Trailing P/E145.3

P25 14.4P50 18P75 31.9

ROE1.6

P25 -16.2P50 0.3P75 9.8

ROIC5.1

P25 -11.7P50 -0.2P75 8.8

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TPEX/6539 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

236

Groups with data

Currency

TWD

Showing 236 of 236 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Taiwan
Country code	TW
Employees	326
Employees Change	10%
Employees Change Percent	3.27
Enterprise value	TWD 891.3M
Exchange	Taipei Exchange
Financial currency	TWD
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	TW0006539000
Last refreshed	2026-05-10
Market cap	TWD 1.2B
Price	TWD 47.95
Price currency	TWD
Rev Per Employee	2,436,125.77x
Sector	Healthcare
Sic	2844
Symbol	tpex/6539
Website	https://www.dvbiomed.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	0.66%
EV Earnings	115.2x
EV/EBIT	59.99x
EV/EBITDA	18.16x
EV/FCF	30.37x
EV/Sales	1.12x
FCF yield	2.51%
P/B ratio	2.3x
P/E ratio	145.3x
P/S ratio	1.47x
PE Ratio10 Y	27.33x
PE Ratio3 Y	51.95x
PE Ratio5 Y	41.91x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	1.87%
EBITDA Margin	4.03%
FCF margin	3.7%
Gross margin	71.35%
Gross Profit	TWD 566.6M
Gross Profit Growth	10.72%
Gross Profit Growth Q	23.54%
Gross Profit Growth3 Y	11.47%
Gross Profit Growth5 Y	-6.5%
Net Income	TWD 7.7M
Net Income Growth	-91.31%
Net Income Growth Q	-69.97%
Net Income Growth Years	0%
Net Income Growth3 Y	-50.27%
Net Income Growth5 Y	-50.43%
Pretax Margin	1.27%
Profit Margin	0.97%
Profit Per Employee	TWD 23,733
Profitable Years	7
ROA	1.28
Roa5y	8.97
ROCE	2.75
ROE	1.55
Roe5y	17.69
ROIC	5.14
Roic5y	26.36

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-13.21%
Cagr1y	-30.03%
Cagr3y	-30.34%
Cagr5y	-16.75%
Div CAGR10	-16.97%
Div CAGR3	-56.65%
Div CAGR5	-42.6%
EPS Growth	-91.37
EPS Growth Q	-68.82
EPS Growth Years	0
EPS Growth3 Y	-50.38
EPS Growth5 Y	-50.46
FCF Growth	-75.02%
FCF Growth Q	-85.94%
FCF Growth5 Y	-32%
OCF Growth	-51.7%
OCF Growth Q	-71.49%
OCF Growth10 Y	-18.83%
OCF Growth3 Y	376.64%
OCF Growth5 Y	-27.26%
Revenue Growth	38.46x
Revenue Growth Q	25.11x
Revenue Growth Quarters	2x
Revenue Growth Years	1x
Revenue Growth3 Y	13.57x
Revenue Growth5 Y	-8.99x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	TWD 1.09
Assets	TWD 677.2M
Cash	TWD 321.8M
Current Assets	TWD 489.1M
Current Liabilities	TWD 137.7M
Debt	TWD 45.5M
Debt EBITDA	TWD 0.93
Debt Equity	TWD 0.09
Debt FCF	TWD 1.55
Equity	TWD 507.4M
Interest Coverage	9.9
Liabilities	TWD 169.8M
Long Term Assets	TWD 188.1M
Long Term Liabilities	TWD 32.1M
Net Cash	TWD 276.3M
Net Cash By Market Cap	TWD 23.66
Net Cash Growth	11.1%
Net Debt EBITDA	TWD -8.63
Net Debt Equity	TWD -0.54
Net Debt FCF	TWD -9.41
Tangible Book Value	TWD 505M
Tangible Book Value Per Share	TWD 20.74
WACC	5.1

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.55
Inventory Turnover	2.41
Net Working Capital	TWD 45.1M
Quick ratio	2.62
Working Capital	TWD 351.4M
Working Capital Turnover	TWD 2.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.09%
Dividend Growth	-74.71%
Dividend Growth Years	0%
Dividend per share	TWD 0.6
Dividend Years	12
Dividend Yield	1.25%
Ex Div Date	2026-06-17
Last Dividend	TWD 0.6
Payout Frequency	Semi-Annual
Payout Ratio	480.08%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-75.75%
1Y total return	-30.01%
200-day SMA	55.58
3Y total return	-66.2%
50-day SMA	52.02
50-day SMA vs 200-day SMA	50under200
5Y total return	-60.01%
All Time High	335.7
All Time High Change	-85.72%
All Time High Date	2016-06-07
All Time Low	45.75
All Time Low Change	4.81%
All Time Low Date	2026-05-07
ATR	1.72
Beta	0.17
Beta1y	0.22
Beta2y	0.27
Ch YTD	-18.73
High	47.95
High52	73.81
High52 Date	2025-05-12
High52ch	-35.04%
Low	45.8
Low52	45.75
Low52 Date	2026-05-07
Low52ch	4.81%
Ma50ch	-7.82%
Price vs 200-day SMA	-13.73%
RSI	40.29
RSI Monthly	32.35
RSI Weekly	32.2
Sharpe ratio	-0.15x
Sortino ratio	-0.08
Total Return	1.34%
Tr YTD	-18.73
Tr1m	-7.79%
Tr1w	1.05%
Tr3m	-18.73%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	TWD 14.9M
Operating Income Growth	-81.56
Operating Income Growth Q	-83.91
Operating Income Growth3 Y	-47.94
Operating Income Growth5 Y	-43.65
Operating margin	1.87

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3,598,566%
Net Borrowing	-21,567,000
Shares Insiders	15.88%
Shares Out	24,349,300
Shares Qo Q	0.06%
Shares Yo Y	-0.09%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	TWD 29.4M
Average Volume	5,815.1x
Bv Per Share	20.84
CAPEX	TWD -28.1M
Ch10y	-84.16
Ch1m	-7.79
Ch1w	1.05
Ch1y	-31.58
Ch3m	-18.73
Ch3y	-70.5
Ch5y	-70.53
Ch6m	-14.37
Change	2.24%
Change From Open	2.24
Close	46.9
Days Gap	0
Depreciation Amortization	17,163,000
Dollar Volume	221,385.2
Earnings Date	2026-05-13
EBIT	TWD 14.9M
EBITDA	TWD 32M
EPS	TWD 0.32
F Score	5
FCF	TWD 29.4M
FCF EV Yield	3.29x
FCF Per Share	TWD 1.21
Financing CF	-58,211,000
Fiscal Year End	December
Founded	2,011
Graham Number	12.1631
Graham Upside	-74.63
Income Tax	TWD 2M
Investing CF	-86,126,000
Is Primary Listing	1
Last Earnings Date	2025-11-13
Last Report Date	2025-12-31
Last Split Date	2025-08-28
Last Split Type	Forward
Lynch Fair Value	TWD 1.58
Lynch Upside	-96.71
Ma150	55.16
Ma150ch	-13.08%
Ma20	49.2
Ma20ch	-2.54%
Net CF	-100,022,000
Next Earnings Date	2026-05-13
Open	46.9
P FCF Ratio	39.78
P OCF Ratio	20.31
Payment Date	2026-07-07
Position In Range	100
Ppne	72,798,000
Price Date	2026-05-08
Price EBITDA	TWD 36.46
Ptbv Ratio	2.31
Relative Volume	0.79x
Revenue	794,177,000x
Tax By Revenue	0.25x
Tax Rate	19.99%
Tr6m	-14.37%
Volume	4,617
Z Score	7.33

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

TPEX/6539 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.3%

$0.60 annual per share

Payout ratio

+480.1%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

-42.6%

0 consecutive years of growth

Total shareholder yield

+1.3%

Next ex-dividend date: 2026-06-17

Performance

TPEX/6539 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TPEX/6539?

Insider, institutional, and short-interest positioning.

Institutional ownership

n/a

Share of float held by funds and institutions

Insider ownership

+15.9%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.1%

Negative means the company is buying back shares.

Technical

TPEX/6539 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

40.3

Neutral momentum band

Price vs 200-day MA

-13.7%

50/200-day relationship not available

Beta (5Y)

0.17

Less volatile than the market

Sharpe ratio

-0.15

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TPEX/6539

Hub-level FAQ points readers to the deeper analysis pages.

What is the current tpex/6539 stock rating?

tpex/6539 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full tpex/6539 analysis?

The full report lives at /stocks/tpex/6539/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for tpex/6539?

The latest report frames tpex/6539 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the tpex/6539 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.